South San Francisco, Calif. — October 7, 2025 — Leads & Copy — Akero Therapeutics, Inc. (Nasdaq: AKRO) will present new data on efruxifermin (EFX) at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, to be held November 7-11 in Washington, DC. The presentations include findings from the 96-week Phase 2b SYMMETRY study and insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY study.
Oral presentations will feature data on improvements in non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY), presented by Vlad Ratziu, M.D., Ph.D., on Sunday, November 9, 2025, at 12:00 PM ET. Another oral presentation will cover the improvement of markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH, presented by Mazen Noureddin, M.D., M.H.Sc., on Sunday, November 9, 2025, at 2:45 PM ET.
A poster presentation will highlight AI-powered histology analysis of HARMONY, revealing Efruxifermin-driven changes in the liver microarchitecture in F2/F3 MASH, presented by Jörn M. Schattenberg, M.D., on Monday, November 10, 2025, from 11:30 AM-12:30 PM ET.
Akero Therapeutics is focused on developing treatments for metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Their lead product candidate, efruxifermin (EFX), is being evaluated in Phase 3 clinical studies.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
IR@akerotx.com
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
Peg.rusconi@deerfieldgroup.com
Source: Akero Therapeutics, Inc.
